Cloud Top New Star (01952.HK): Nephrocolnial 7 latest real-world data will be unveiled at the 18th International IgA Nephropathy Symposium.

According to the Wisdom Financial APP, the 18th International IgA Nephropathy Conference (IIgANN) in 2025 will be held in Prague, Czech Republic from September 17th to 20th. NEFECON (budesonide enteric capsules) will present 7 latest real-world data at this event, further demonstrating its deep research progress in the field. NEFECON is currently the world's first IgA nephropathy treatment drug that has been fully approved by the National Medical Products Administration (NMPA) of China, the Food and Drug Administration (FDA) of the United States, the European Medicines Agency (EMA), the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom, and other authorized regions in Asia (Hong Kong, Macau, Taiwan, Singapore, and Korea) by Yunding Xinyao (01952.HK).